New 2026 Cell and Gene Therapy Report Charts the Path from Scientific Progress to Patient Access

What happened: InspiroGene by McKesson published its third annual 2026 Cell and Gene Therapy Report, combining provider research across oncology, rheumatology and ophthalmology with payer, patient and advocate insights and pipeline analysis. Key numbers: 200 U.S. Why it matters: The report states that commercial patient access needs to move as quickly as scientific progress, and that closing the gap requires the ecosystem to evolve from patient identification and referral to provider preparation, payer reimbursement and care delivery.

InspiroGene by McKesson published its third annual 2026 Cell and Gene Therapy Report, combining provider research across oncology, rheumatology and ophthalmology with payer, patient and advocate insights and pipeline analysis.

The report states that commercial patient access needs to move as quickly as scientific progress, and that closing the gap requires the ecosystem to evolve from patient identification and referral to provider preparation, payer reimbursement and care delivery.